# Revascularization of Stenosed Vessels Using Optimized Treatment of Rejuveinix for Reversing Endothelial Dysfunction

> **NCT03041259** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Reven Pharmaceuticals, Inc.** · enrollment: 320 (estimated)

## Conditions studied

- Critical Limb Ischemia
- Peripheral Arterial Disease

## Interventions

- **DRUG:** Rejuveinix Low Dose
- **DRUG:** Rejuveinix High Dose

## Key facts

- **NCT ID:** NCT03041259
- **Lead sponsor:** Reven Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01
- **Primary completion:** 2022-01
- **Final completion:** 2022-07
- **Target enrollment:** 320 (ESTIMATED)
- **Last updated:** 2018-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03041259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03041259, "Revascularization of Stenosed Vessels Using Optimized Treatment of Rejuveinix for Reversing Endothelial Dysfunction". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03041259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*